Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or
Patents for C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
01/2006
01/04/2006EP1383741A4 Process for the preparation of benazepril
01/04/2006CN1715280A Aryl fused azapolycyclic compounds
01/03/2006US6982277 Antitumor agents, antiinflammatory agents; for example 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-yl)-1-(4-methylphenyl) -1-ethanone, 2-(4-methylphenyl)-5,6,7,8-tetrahydrobenzo(d)-imidazo(2,1-b)thiazole
01/03/2006CA2253635C Use of aspirochlorine or derivatives thereof as immunosuppressive agents
12/2005
12/29/2005WO2005123727A1 3-aryl-3-hydroxy- and 3-aryl-3-oxopropionic acid esters as fungicides
12/29/2005WO2005123672A2 Kinase inhibitors
12/29/2005WO2005108403A3 Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity
12/29/2005WO2005097089A9 Derivatives of leinamycin for use as anticancer agents
12/29/2005WO2005062882A3 Rifamycin analogs and uses thereof
12/29/2005WO2005051974A3 Novel molecules for regulating cell death
12/29/2005US20050288282 Anticancer agents; antiproliferative agents
12/28/2005EP1608662A1 Guanidine derivatives and use thereof as neuropeptide ff receptor antagonists
12/28/2005EP1461318B9 Tetrahydroquinoline analogues as muscarinic agonists
12/28/2005EP1224183B1 Heterocyclic sodium/proton exchange inhibitors and method
12/28/2005EP1031563B1 Sulfonyl derivatives
12/22/2005WO2005121153A1 Condensed pyrimidine derivative and xanthine oxidase inhibitor
12/22/2005WO2005121130A2 Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
12/22/2005WO2005121100A1 Melanocortin-4 receptor binding compounds and methods of use thereof
12/22/2005WO2005111031A3 Neuropeptide receptor modulators
12/22/2005WO2005058231A3 Rifamycin analogs and uses thereof
12/22/2005US20050282874 For therapy of allergic disorders (e.g., immunodeficiency diseases and hypersensitivity); cardiovascular disorders (e.g., hypertension and arteriosclerosis); dental and oral disorders (e.g., inflammation of the oral mucosa); dermatologic disorders (e.g., dermatitis and skin infections)
12/22/2005US20050282858 Substituted cycloalkylcarboxamides: 1-((1-(4-Chlorophenyl)cyclopropyl)carbonyl)pyrrolidin-3-ol and 1-Acetyl-4-(4-{1-[(3-phenylpyrrolidin-1-yl)carbonyl]cyclopropyl}phenyl)piperazine; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; antidiabetic agents
12/22/2005US20050282851 antidiabetic agents such as 3-Cyclopentyl-2-(4-methanesulfonyl-phenyl)-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-propionamide, used for prevention and treatment of impaired glucose tolerance, non-insulin dependent diabetes and obesity
12/22/2005US20050282815 Substituted N-(heteroar-beta-yl)aminopyridinecarboxamides or benzamides, e.g., 2-amino-4-fluoro-5-(1-methyl-1H-imidazol-2-ylsulfanyl)-N-(4-methylthiazol-2-yl)benzamide; glucokinase activators used to treat diabetes mellitus or obesity
12/22/2005US20050282796 Tetracyclic azepinoindole compounds
12/22/2005CA2569111A1 Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
12/22/2005CA2529445A1 Melanocortin-4 receptor binding compounds and methods of use thereof
12/21/2005EP1606254A1 2,4,6-phenyl substituted cyclic ketoenols
12/21/2005EP1605938A2 Antibacterial agents
12/21/2005CN1711272A N-sulfonylaminothiazole
12/21/2005CN1232520C Salts of bicyclic N-acylated imidazo-3-amines and imidazo-5-amines
12/21/2005CN1232508C Cyclization process step in making of quinolones and phenodiazine
12/20/2005US6977263 Chemical compounds
12/20/2005CA2159481C Tetracyclic compounds as dopamine agonists
12/15/2005WO2005118589A1 Bicyclic heterocycles as hiv integrase inhibitors
12/15/2005WO2005118549A2 Compounds having affinity for dopamine d3 receptor and uses thereof
12/15/2005WO2005118537A2 Arylpiperazine derivatives as adrenergic receptor antagonists
12/15/2005WO2005117890A2 Thienopyrimidines and thiazolopyrimidines for use in medicine
12/15/2005WO2004014313A3 Combination pharmaceutical agents as inhibitors of hcv replication
12/15/2005US20050277684 Effective under oxidative cellular environment; inhibits the growth of prostate cells by inhibiting DNA synthesis, more particularly by DNA cleavage; TG-25; prostate cancer; synergystic use with other agents like radiation, chemotherapeutic, an inhibitor of DNA repair, etoposide, or anticancer agents
12/15/2005US20050277676 M3muscarinic acetylcholine receptor antagonists
12/15/2005US20050277663 3-Aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides
12/15/2005US20050277659 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
12/15/2005US20050277635 Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds
12/15/2005US20050277630 Antibacterial agents
12/14/2005EP1603922A1 Porphyrin derivatives
12/14/2005CN1708493A Selected CGRP antagonists, method for production and use thereof as medicament
12/14/2005CN1231762C Method for directly identifying candidate compound
12/13/2005US6974802 Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine
12/08/2005WO2005116002A2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
12/08/2005WO2005034940A3 Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases
12/08/2005WO2005009384A3 Egfr tyrosine kinase inhibitors
12/08/2005WO2004078682A3 Cyclic compounds and compositions as protein kinase inhibitors
12/08/2005US20050272791 Lung melanoma metastasis, rheumatoid arthritis, 1-isopropylsulfonyl-2-amino-6-(2-(2,6-difluorophenyl)-5-(phenyl)-imidazol-4-yl)-benzimidazole
12/08/2005US20050272750 Novel compound
12/08/2005US20050272745 Novel piperidine and piperazine derivatives
12/08/2005US20050272736 Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
12/07/2005EP1602659A1 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
12/07/2005EP1601678A2 Fused pyrrole compounds
12/07/2005EP1601676A2 Fused imidazoles as transforming growth factor (tgf) inhibitors
12/07/2005EP1601673A1 Novel fused heterocycles and uses thereof
12/07/2005EP1171442B1 Xanthine derivatives and analogs as cell signalling inhibitors
12/07/2005EP1049466B1 Carbonic anhydrase inhibitor for increasing oxygen tension in the optic nerve and retina
12/07/2005CN1704419A Process for synthesis of prulifloxacin and its pharmaceutical composition
12/07/2005CN1704404A Tricyclic protein kinase inhibitors
12/07/2005CN1230431C Arylmethylamine derivatives for use as tryptase inhibitors
12/06/2005US6972299 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
12/06/2005US6972295 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis
12/01/2005WO2005113536A2 Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
12/01/2005WO2005113526A2 Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
12/01/2005WO2005112923A2 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
12/01/2005WO2005060963A8 Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
12/01/2005US20050267303 Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals
12/01/2005US20050267182 Urea derivatives as FLT-3 modulators
12/01/2005US20050267152 Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/01/2005US20050267132 6-Hydroxy-2,5-dioxo-1,2,3,5-tetrahydro-imidazo[1, 2-a]pyrimidine-7-carboxylic amide derivatives; lymphadenopathy associated virus and human T-cell leukemia/lymphoma virus treatment; AIDS
12/01/2005CA2567352A1 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
11/2005
11/30/2005EP1600442A1 Heteroarylcarbamoylbenzene derivative
11/30/2005EP1599206A2 Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
11/30/2005CN1703408A Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
11/30/2005CN1703401A Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/30/2005CN1229377C Spiro [Piperidine-4,1'-pyrrolo[3,4-c] pyrrole]
11/30/2005CN1229323C Dialkoyl-halogen phenyl substituted keto-enol
11/29/2005US6969713 Piperidine and piperazine acetamide derivatives
11/29/2005CA2318160C Asymmetric cyanine dye quenchers
11/29/2005CA2244245C Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
11/24/2005WO2005111039A2 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
11/24/2005WO2005111031A2 Neuropeptide receptor modulators
11/24/2005WO2005110992A1 Amido compounds and their use as pharmaceuticals
11/24/2005WO2005110422A2 Treatment of diseases associated with altered level of amyloid beta peptides
11/24/2005US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis
11/24/2005US20050261315 tyrosine kinase inhibitors such as N-(3-tert-butylisoxazol-5-yl)-2-(4-(benzyloxy)phenyl)acetamide, used for treating and preventing conditions and diseases, such as cancer, hematologic malignancies, cardiovascular disease, inflammation or multiple sclerosis
11/24/2005US20050260126 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
11/24/2005CA2567223A1 Treatment of diseases associated with altered level of amyloid beta peptides
11/24/2005CA2565238A1 Amido compounds and their use as pharmaceuticals
11/24/2005CA2564751A1 Neuropeptide receptor modulators
11/23/2005EP1597260A1 Triazole compounds useful in therapy
11/23/2005EP1597256A1 N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
11/23/2005EP1597246A2 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
11/23/2005CN1699372A Process for synthesizing lornoxicam intermediate against inflammation and pain
1 ... 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 ... 152